000 | 01986 a2200541 4500 | ||
---|---|---|---|
005 | 20250514215030.0 | ||
264 | 0 | _c20050414 | |
008 | 200504s 0 0 eng d | ||
022 | _a0022-5223 | ||
024 | 7 |
_a10.1016/j.jtcvs.2004.06.048 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aKeshavjee, S | |
245 | 0 | 0 |
_aA randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. _h[electronic resource] |
260 |
_bThe Journal of thoracic and cardiovascular surgery _cFeb 2005 |
||
300 |
_a423-8 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aBiomarkers _xblood |
650 | 0 | 4 | _aCardiopulmonary Bypass |
650 | 0 | 4 |
_aComplement Inactivator Proteins _xantagonists & inhibitors |
650 | 0 | 4 |
_aComplement System Proteins _xdrug effects |
650 | 0 | 4 | _aDouble-Blind Method |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGraft Rejection _xetiology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aLength of Stay |
650 | 0 | 4 |
_aLung Diseases _xmortality |
650 | 0 | 4 | _aLung Transplantation |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 | _aNorth America |
650 | 0 | 4 |
_aOxygen Consumption _xdrug effects |
650 | 0 | 4 |
_aPostoperative Complications _xetiology |
650 | 0 | 4 |
_aReceptors, Complement _xantagonists & inhibitors |
650 | 0 | 4 |
_aReperfusion Injury _xetiology |
650 | 0 | 4 | _aRespiration, Artificial |
650 | 0 | 4 |
_aSurgical Wound Infection _xetiology |
650 | 0 | 4 | _aSurvival Analysis |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aDavis, R D | |
700 | 1 | _aZamora, M R | |
700 | 1 | _ade Perrot, M | |
700 | 1 | _aPatterson, G A | |
773 | 0 |
_tThe Journal of thoracic and cardiovascular surgery _gvol. 129 _gno. 2 _gp. 423-8 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jtcvs.2004.06.048 _zAvailable from publisher's website |
999 |
_c15355870 _d15355870 |